Heat Biologics announces clinical trial combining HS-110 and PD-1 checkpoint inhibitor
Heat Biologics announced that it has enrolled the first patient in a Phase 1b clinical trial investigating the combination of its HS-110 therapeutic vaccine and the Bristol-Myers Squibb PD-1 inhibitor nivolumab (Opdivo®) in non-small cell lung cancer. September 01, 2015